Bio-Solutions Corp.
OTC Bulletin Board : BISU

Bio-Solutions Corp.

March 29, 2010 14:00 ET

Bio-Solutions Corp.: Good People Doing Good Things

MONTREAL, CANADA--(Marketwire - March 29, 2010) - Bio-Solutions Corp. (OTCBB:BISU), is proud to announce, President and CEO Gilles Chaumillon is now the Latest addition to www.ceocfointerviews.com

http://ceocfointerviews.com/interviews/BISU-BioSolutions10.htm

The direct link above, will give the everyday Investor a better chance to get to know Bio-solutions Corp and the Management behind the company. 

On the Bio-Solutions Corp. Profile page there is a company description, CEO Description and a one on one Q&A session with Gilles regarding Bio-Solutions, its product line, and their target market. Bio's main goal is fighting, treating and preventing, areas afflicted by Malaria.

At Bio-Solutions Corp we market new and very effective FDA approved organic product to counter Malaria; our lead product is GREENEX™. Malaria is the forefront of priorities for the World Health Organization (WHO).

"GREENEX™ is an organic insecticide available in solid or liquid form, it neutralizes and eradicates up to 98% of the mosquito larvae, within a 24 hours period. Today, Malaria is the most dangerous disease transmitted by mosquitoes that we know of. Over 300 million people are infected by this disease and more than one million children under the age of five years die from Malaria each year" stated Dr Chaumillon.

For more information on Bio-Solutions Corp. and its products, please visit the company's website at www.bio-solutionscorp.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of studies, the ability of the Company to take advantage of business opportunities in the biotechnology industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.

Contact Information